Mantle cell lymphoma, response to treatment and prognosis in 45 patients

被引：0

作者：

Sorigue, Marc ^{[1
]}

Sancho, Juan-Manuel ^{[1
]}

Garcia, Olga ^{[1
]}

Vila, Jordi ^{[1
]}

Moreno, Miriam ^{[1
]}

Ribera, Josep-Maria ^{[1
]}

机构：

[1] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, ICO,Serv Hematol Clin, E-08193 Barcelona, Spain

来源：

MEDICINA CLINICA | 2016年 / 147卷 / 01期

关键词：

Mantle cell lymphoma; High-dose cytarabine; Prognosis; CLINICAL-PRACTICE GUIDELINES; PROGRESSION-FREE SURVIVAL; FOLLOW-UP; MULTICENTER; RITUXIMAB; DIAGNOSIS; TRIAL;

D O I：

10.1016/j.medcli.2016.03.016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background and purpose: Mantle cell lymphoma (MCL) is a rare lymphoproliferative disorder, with frequent relapses and a poor prognosis. This study analyzes response to treatment and prognosis in a series of MCL patients. Patients and method: Retrospective study of MCL patients diagnosed in a single institution between 1996 and 2013. The cohort was divided according to the treatment received. Results: Forty-five patients were included (32 male) with a median age of 66 years old. Twenty-one received intensive chemotherapy or chemoimmunotherapy (based on high-dose cytarabine), 13 semi intensive (without high-dose cytarabine), 8 not intensive and 3 did not require treatment. Overall response rate was 85% in the intensive and 77% in the semi-intensive treatment groups. In multivariate analysis, intensive treatment was correlated with a longer progression-free survival (hazard ratio 9.8 [95% CI 2.7-35.5], P = .001) and overall survival (4.5 [1.2-17.8], P = .03). Conclusions: In this retrospective series of MCL patients, intensive treatment was correlated with better outcomes than the other treatment modalities. (C) 2016 Elsevier Espana, S.L.U. All rights reserved.

引用

页码：18 / 21

页数：4

共 10 条

[1] Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group [J].

Caballero, Dolores ;

Campo, Elias ;

Lopez-Guillermo, Armando ;

Martin, Alejandro ;

Arranz-Saez, Reyes ;

Gine, Eva ;

Lopez, Andres ;

Gonzalez-Barca, Eva ;

Angel Canales, Miguel ;

Gonzalez-Diaz, Marcos ;

Orfao, Alberto .

ANNALS OF HEMATOLOGY, 2013, 92 (09) :1151-1179

[2] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[3] Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center [J].

Chihara, Dai ;

Cheah, Chan Y. ;

Westin, Jason R. ;

Fayad, Luis E. ;

Rodriguez, Maria A. ;

Hagemeister, Fredrick B. ;

Pro, Barbara ;

McLaughlin, Peter ;

Younes, Anas ;

Samaniego, Felipe ;

Goy, Andre ;

Cabanillas, Fernando ;

Kantarjian, Hagop ;

Kwak, Larry W. ;

Wang, Michael L. ;

Romaguera, Jorge E. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (01) :80-88

[4] Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network [J].

Dreyling, M ;

Lenz, G ;

Hoster, E ;

Van Hoof, A ;

Gisselbrecht, C ;

Schmits, R ;

Metzner, B ;

Truemper, L ;

Reiser, M ;

Steinhauer, H ;

Boiron, JM ;

Boogaerts, MA ;

Aldaoud, A ;

Silingardi, V ;

Kluin-Nelemans, HC ;

Hasford, J ;

Parwaresch, R ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2005, 105 (07) :2677-2684

[5] Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Dreyling, M. ;

Geisler, C. ;

Hermine, O. ;

Kluin-Nelemans, H. C. ;

Le Gouill, S. ;

Rule, S. ;

Shpilberg, O. ;

Walewski, J. ;

Ladetto, M. .

ANNALS OF ONCOLOGY, 2014, 25 :83-92

[6] Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group [J].

Geisler, Christian H. ;

Kolstad, Arne ;

Laurell, Anna ;

Andersen, Niels S. ;

Pedersen, Lone B. ;

Jerkeman, Mats ;

Eriksson, Mikael ;

Nordstrom, Marie ;

Kimby, Eva ;

Boesen, Anne Marie ;

Kuittinen, Outi ;

Lauritzsen, Grete F. ;

Nilsson-Ehle, Herman ;

Ralfkiaer, Elisabeth ;

Akerman, Mans ;

Ehinger, Mats ;

Sundstrom, Christer ;

Langholm, Ruth ;

Delabie, Jan ;

Karjalainen-Lindsberg, Marja-Liisa ;

Brown, Peter ;

Elonen, Erkki .

BLOOD, 2008, 112 (07) :2687-2693

[7] A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma [J].

Hoster, Eva ;

Dreyling, Martin ;

Klapper, Wolfram ;

Gisselbrecht, Christian ;

van Hoof, Achiel ;

Kluin-Nelemans, Hanneke C. ;

Pfreundschuh, Michael ;

Reiser, Marcel ;

Metzner, Bernd ;

Einsele, Hermann ;

Peter, Norma ;

Jung, Wolfram ;

Woermann, Bernhard ;

Ludwig, Wolf-Dieter ;

Duehrsen, Ulrich ;

Eimermacher, Hartmut ;

Wandt, Hannes ;

Hasford, Joerg ;

Hiddemann, Wolfgang ;

Unterhalt, Michael .

BLOOD, 2008, 111 (02) :558-565

[8] Treatment of Older Patients with Mantle-Cell Lymphoma [J].

Kluin-Nelemans, H. C. ;

Hoster, E. ;

Hermine, O. ;

Walewski, J. ;

Trneny, M. ;

Geisler, C. H. ;

Stilgenbauer, S. ;

Thieblemont, C. ;

Vehling-Kaiser, U. ;

Doorduijn, J. K. ;

Coiffier, B. ;

Forstpointner, R. ;

Tilly, H. ;

Kanz, L. ;

Feugier, P. ;

Szymczyk, M. ;

Hallek, M. ;

Kremers, S. ;

Lepeu, G. ;

Sanhes, L. ;

Zijlstra, J. M. ;

Bouabdallah, R. ;

Lugtenburg, P. J. ;

Macro, M. ;

Pfreundschuh, M. ;

Prochazka, V. ;

Di Raimondo, F. ;

Ribrag, V. ;

Uppenkamp, M. ;

Andre, M. ;

Klapper, W. ;

Hiddemann, W. ;

Unterhalt, M. ;

Dreyling, M. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :520-531

[9] Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [J].

Rummel, Mathias J. ;

Niederle, Norbert ;

Maschmeyer, Georg ;

Banat, G. Andre ;

von Gruenhagen, Ulrich ;

Losem, Christoph ;

Kofahl-Krause, Dorothea ;

Heil, Gerhard ;

Welslau, Manfred ;

Balser, Christina ;

Kaiser, Ulrich ;

Weidmann, Eckhart ;

Duerk, Heinz ;

Ballo, Harald ;

Stauch, Martina ;

Roller, Fritz ;

Barth, Juergen ;

Hoelzer, Dieter ;

Hinke, Axel ;

Brugger, Wolfram .

LANCET, 2013, 381 (9873) :1203-1210

[10]

Vardiman JW., 2008, WHO CLASSIFICATION T

← 1 →